GeneTex

  • Country / Location Selection

United States (US)

Cancer Tissue Gallery- GTX04443

TACSTD2 antibody [MSVA-733R] HistoMAXTM

 

Go to Normal Tissue Gallery Go back to product page Go to HistoMAX page

 

Breast- Invasive breast cancer of no special type (NST) with strong TACSTD2 immunostaining of tumor cells.
Breast- Invasive lobular breast cancer with weak to moderate TACSTD2 immunostaining of tumor cells. Note: TACSTD2 staining is more intense in a normal breast gland.
Colon- Colorectal adenocarcinoma with a weak to moderate TACSTD2 immunostaining in few tumor cells.
Esophagus- Adenocarcinoma with strong TACSTD2 immunostaining of tumor cells.
Esophagus- Squamous cell carcinoma showing a strong, predominantly membranous TACSTD2 tumor cell positivity.
Kidney- Chromophobe renal cell carcinoma exhibiting a strong membranous TACSTD2 staining of tumor cells.
Kidney- Intense, predominantly membranous TACSTD2 positivity of tumor cells in a papillary renal cell carcinoma.
Kidney- TACSTD2 negative clear cell renal cell carcinoma.
Liver- TACSTD2 negative hepatocellularcellular carcinoma.
Lung- Adenocarcinoma with strong membranous TACSTD2 staining of tumor cells.
Lung- Malignant mesothelioma with moderate membranous TACSTD2 immunostaining in a small fraction of tumor cells.
Lung- Squamous cell carcinoma with strong TACSTD2 immunostaining of tumor cells.
Lung- TACSTD2 negative malignant mesothelioma (epitheloid).
Ovary- Endometroid carcinoma with strong TACSTD2 positivity in 70% of tumor cells.
Ovary- Serous high-grade carcinoma with strong TACSTD2 immunostaining of >90% of tumor cells. A few intermingled tumor cells show much weaker positivity.
Ovary- Serous high-grade carcinoma with strong, predominantly membranous TACSTD2 immunostaining of tumor cells.
Pancreas- TACSTD2 negative neuroendocrine tumor.
Prostate- Adenocarcinoma (Gleason 3+3=6) with strong TACSTD2 immunostaining of tumor cells.
Salivary gland- Warthin tumor with intense predominantly membranous TACSTD2 staining of tumor cells.
Stomach- Gastric adenocarcinoma (diffuse type) with weak to moderate TACSTD2 immunostaining of most tumor cells.
Stomach- Gastric adenocarcinoma with weak to moderate membranous TACSTD2 immunostaining of a small fraction of tumor cells.
Stomach- TACSTD2 negative gastrointestinal stromal tumor (GIST).
Testis- TACSTD2 negative Leydig cell tumor.
Testis- TACSTD2 negative seminoma.
Thyroid- Papillary cancer with strong TACSTD2 positivity of tumor cells.
Thyroid- TACSTD2 negative medullary carcinoma.
Urinary bladder- Muscle-invasive urothelial carcinoma showing a strong TACSTD2 positivity of tumor cells.
Vulva- Squamous cell carcinoma showing strong TACSTD2 immunostaining.

| TOP |